Sandra Pérez Baos

Excited to share our latest @2048vc thesis series. Here you will find our Our Thesis on Reproductive Longevity. If you are a founder in this space, please reach out! This post was written by @IskoldLilly and @sperezbaos, with input from @JulieMarieWolf, and and originally appeared on the 2048 Ventures Blog: 2048.vc/blog/our-thesi… --- We believe reproductive healthspan will be one of the first domains where longevity science translates into clinical impact. At 2048 Ventures, we invest in early-stage startups building defensibility through technology and proprietary data. Reproductive longevity is an area we’ve been increasingly excited about, where new biological breakthroughs and data-driven approaches are enabling a new generation of startups. Longevity continues to be a defining theme of the future of healthcare and we believe reproductive healthspan will be one of the first domains where longevity science translates into clinical impact. Reduced ovarian function is one of the earliest measurable signs of systemic aging. Despite decades of innovation in assisted reproduction, the biological drivers of fertility decline remain largely unaddressed. In our view, the most compelling technology targets the biological drivers of reproductive aging. As our ability to measure and intervene in reproductive biology improves, care will increasingly shift from reactive treatment toward earlier measurement, prediction, and preventative intervention. We see a future where OB-GYNs routinely assess ovarian aging and fertility risk, forecast reproductive trajectories, and proactively intervene to extend reproductive healthspan. Inevitabilities Shaping the Future of Reproductive Longevity We see several inevitabilities: 1. Delayed parenthood will widen the gap between peak biological fertility and the timing of first birth. We are already seeing this demographic shift. 2. Reproductive biology will become a quantified system in which we can measure, predict, and intervene. Core drivers of reproductive aging (e.g., oocyte quality, ovarian function, endometrial receptivity) are becoming measurable at high resolution and over time. This data will enable prediction, personalization, and more precise intervention selection across the reproductive timeline. 3. A growing share of reproductive health will be technology-mediated. Assisted reproduction is broadly accepted socially and no longer confined to infertility. Technological intervention will become embedded in a growing proportion of pregnancies over time. Bottlenecks and Opportunities Created These inevitabilities highlight several gaps that still limit progress in the space: - Proactive reproductive health monitoring is still lacking: Most fertility decisions are made with incomplete and reactive information. In addition, the timing of menopause remains largely unpredictable. There is an opportunity to develop longitudinal measurement tools and predictive models to map ovarian aging and enable earlier decisions around fertility preservation and proactive management of menopausal transition. - Biological drivers of fertility remain poorly addressed: Despite widespread adoption of assisted reproduction, success rates remain far from guaranteed and decline sharply with age. There is an opportunity to develop interventions that 1) address core biological failure points (e.g. improve oocyte quality, boost implantation), and 2) build predictive decision support systems that can improve outcomes. - Models of implantation biology are limited: The maternal-fetal interface and implantation involve complex interactions that are hard to reproduce in vitro, limiting both diagnostic and therapeutic innovation. There is an opportunity to develop models with human relevance that unlock proprietary datasets linked to clinical outcomes. Where Reproductive Longevity Intersects with Our Core Theses: We’re excited about this space because it sits at the intersection of the inevitabilities mentioned above, significant whitespace for innovation, and many of the core theses that anchor our investing at 2048 Ventures. - Proprietary biological data and data defensibility: New biological models of ovarian aging, implantation, and the maternal-fetal interface can enable differentiated diagnostics and therapeutics, while generating proprietary, outcome-linked datasets. - Compounding data and biobank moats: Reproductive medicine produces uniquely rich biological material—oocytes, embryos, endometrial samples—alongside longitudinal clinical data. Over time, this can evolve into proprietary biobanks and defensible data assets across fertility, maternal health, and longevity. - Direct intersection with longevity science: Ovarian aging is one of the earliest measurable manifestations of systemic aging. Interventions that preserve or restore reproductive function provide a direct way to extend reproductive healthspan with clear biological endpoints. Companies We Want to Meet: We see three core categories of companies that represent the most compelling opportunities in this space: - Diagnostics that guide biological intervention, specifically technologies that quantify egg quality, biological ovarian age, endometrial receptivity, and other reproductive biomarkers that enable earlier detection of reproductive decline. These tools will be used by clinicians to guide decisions around fertility preservation, IVF strategy, and therapeutic intervention. - Early therapeutic interventions designed to extend reproductive healthspan by preserving ovarian reserve, improving oocyte quality or quantity, and modulating the biological drivers of ovarian aging. These can also be platforms that improve IVF outcomes by addressing implantation failure, embryo viability, and immune factors. - Next-generation biological model infrastructure, ranging from engineered tissues to multimodal platforms, that enable faster testing and intervention development across ovarian aging and the maternal–fetal interface. If you're a founder working in the space, we'd love to connect: 2048.vc/pitch-us

We are thrilled to announce our latest investment in @NionyxBio! Read more about why we invested 👇 2048.vc/blog/our-inves… 💡 Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases. 👩‍💻 The Founders: @Mtyrpien & Leszek Lisowski 📌 Location: New York 💰 Investment Stage: Seed

Pre-Seed should not take months and months to raise! We are thrilled to announce that @2048vc is launching Pre-Seed Fast Track to help you get funding in 10 business days. If you are raising $500K - $1.5M Pre-Seed round in Vertical AI, Deep Tech, Health or Bio we would love to meet you! We offer clear and transparent process and money in the bank within 10 business days of the first meeting. To start the process submit your pitch through our short form - 2048.vc/fasttrack_pitch If there is a potential fit we will reach out within a few days and follow these steps to fund you: Step 1: Intro meeting via Zoom: 30 mins where you meet with 1 member of our team. Step 2: Deep Dive via Zoom: 60 mins where you meet with 3-4 members of our team. Step 3: References + In-Person Meeting: We will chat with your early customers and professional references, and will spend a few hours to get to know each other in person. Startups are long journeys and we know how important the investor-founder fit is, so we will gladly pay for your travel. Step 4: Term sheet: We make you an offer from $250K - $750K Step 5: Wire: We are high conviction and don’t wait for the rest of the round to come together - we wire as soon as we sign the docs. To learn more about Pre-Seed Fast Track visit 2048.vc/fasttrack. We can’t wait to review your pitches and to meet you! @2048vc // #preseed

Pre-Seed should not take months and months to raise! We are thrilled to announce that @2048vc is launching Pre-Seed Fast Track to help you get funding in 10 business days. If you are raising $500K - $1.5M Pre-Seed round in Vertical AI, Deep Tech, Health or Bio we would love to meet you! We offer clear and transparent process and money in the bank within 10 business days of the first meeting. To start the process submit your pitch through our short form - 2048.vc/fasttrack_pitch If there is a potential fit we will reach out within a few days and follow these steps to fund you: Step 1: Intro meeting via Zoom: 30 mins where you meet with 1 member of our team. Step 2: Deep Dive via Zoom: 60 mins where you meet with 3-4 members of our team. Step 3: References + In-Person Meeting: We will chat with your early customers and professional references, and will spend a few hours to get to know each other in person. Startups are long journeys and we know how important the investor-founder fit is, so we will gladly pay for your travel. Step 4: Term sheet: We make you an offer from $250K - $750K Step 5: Wire: We are high conviction and don’t wait for the rest of the round to come together - we wire as soon as we sign the docs. To learn more about Pre-Seed Fast Track visit 2048.vc/fasttrack. We can’t wait to review your pitches and to meet you! @2048vc // #preseed

We’re hiring an Associate for the @2048vc team in Boston! 🚀 We lead a dozen+ pre-seed and seed rounds each year across Vertical AI, Deep Tech, Health, and Bio. We love being the first YES & we're incredibly privileged to work with founders at the earliest moments in their journeys. Boston has become one of the most exciting places to do that: world-class schools, labs, and a growing community of ambitious founders. So we’re doubling down. This is a rare hire for us. You’ll be on the ground with me sourcing, meeting founders, supporting on deals, and helping to build a preeminent pre/seed fund. The sweet spot: 2–5 years of experience, prior venture/early-stage investing exposure, and a strong network. Ideally already in Boston or happy to relocate. Please help me spread the word! Link and application below